AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9065105
Drug: Intravenous gamma‐globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gamma‐globulin 1 gm/kg per week
Trial: 9065105
Drug: Intravenous gamma‐globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gamma‐globulin 1 gm/kg per week with dexamethasone
Trial: 9065105
Drug: Salvage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage treatment with 60 mg of prednisone per day
Trial: 1326165
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment with myelopid (MP)
Trial: 1326165
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with myelopid (MP)
Trial: 6418094
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg/day) + Nifedipine (30 mg/day)
Trial: 6418094
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg/day) + Placebo (3 tablets/day)
Trial: 6418094
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg/day) + Placebo (3 tablets/day) during Phase II
Trial: 26577065
Drug: 10mg oral
RxNorm normalized name: OPIPZA 10mg Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg oral pure THCV administered daily for five days
Trial: 26577065
Drug: 1mg intravenous
RxNorm normalized name: bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1mg intravenous THC administered on the fifth day
Trial: 26577065
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered daily for five days
Trial: 26577065
Drug: THCV in
RxNorm normalized name: THCV
DrugBank: Tetrahydrocannabivarin (DB11755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THCV in combination with THC
Trial: 24438504
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with sorafenib (800 mg daily) and transcatheter arterial infusion (TAI) with cisplatin (65 mg/m2/cycle)
Trial: 18678161
Drug: Shu-needling therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shu-needling therapy
Trial: 15951542
Drug: Mesalazine enema
RxNorm normalized name: mesalamine Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine enema (1 g at bedtime)
Trial: 8852905
Drug: 5-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-valent pneumococcal conjugate vaccine (PCV)
Trial: 1642935
Drug: IV diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV diclofenac 2 mg kg‐1/24 h for 2 days
Trial: 6377959
Drug: Oral controlled‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral controlled‐release morphine (MST 30 mg)
Trial: 22243564
Drug: Aleurone-rich cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aleurone-rich cereal products (27 g aleurone/d)
Trial: 18581941
Drug: Albuterol (ALB,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (ALB, 16 mg x d(-1))
Trial: 2244710
Drug: Albuterol (ALB)
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (ALB)
Trial: 7604951
Drug: Oral terfenadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terfenadine 60 mg twice daily
Trial: 7604951
Drug: Oral astemizole
RxNorm normalized name: Astemizole
DrugBank: Astemizole (DB00637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral astemizole 10 mg once daily
Trial: 2113796
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg orally
Trial: 18441772
Drug: Dapsone gel
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone gel 5% (n=578)
Trial: 18441772
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel (n=547)
Trial: 14514389
Drug: Bromocriptine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (2.5 mg bid for 14 days)
Trial: 14514389
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment influencing prolactin or other sexual hormones)
Trial: 10611136
Drug: Methoxsalen (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxsalen (50 mg oral)
Trial: 2524549
Drug: MSD recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSD recombinant DNA hepatitis B vaccine (2 micrograms doses, 3 doses I.M. at monthly intervals)
Trial: 2524549
Drug: SKF recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKF recombinant DNA hepatitis B vaccine (2 micrograms doses, 3 doses I.M. at monthly intervals)
Trial: 2524549
Drug: MSD plasma-derived
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSD plasma-derived vaccine (2 micrograms doses, 3 doses I.M. at 0, 1, 2 months)
Trial: 1201630
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly dose-fractionation (12 fractions in 28 days)
Trial: 1201630
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly dose-fractionation (6 fractions in 18 days)
Trial: 31160251
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: ipilimumab 3 mg/kg plus nivolumab 1 mg/kg, two cycles every 3 weeks
Trial: 31160251
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: ipilimumab 1 mg/kg plus nivolumab 3 mg/kg, two cycles every 3 weeks
Trial: 31160251
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: ipilimumab 3 mg/kg for two cycles every 3 weeks followed by nivolumab 3 mg/kg for two cycles every 2 weeks
Trial: 29381993
Drug: Nefopam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (20 mg in 98 mL saline for 20 minutes after induction)
Trial: 29381993
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 mL saline)
Trial: 23874094
Drug: Cefuroxime 250
RxNorm normalized name: cefuroxime 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 250 mg twice daily for mild-moderate exacerbation or 500 mg twice daily for severe exacerbation for 7 days
Trial: 21208909
Drug: F4 protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F4 protein (10, 30, or 90 μg/dose) adjuvanted with AS01
Trial: 21208909
Drug: F4 protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F4 protein (10, 30, or 90 μg/dose) reconstituted with water for injection
Trial: 19805690
Drug: Flow cytometric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow cytometric measurement of minimal residual disease (MRD) at day 15 of induction therapy
Trial: 17426059
Drug: GVD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVD regimen (gemcitabine 1000 mg/m², vinorelbine 20 mg/m², pegylated liposomal doxorubicin 15 mg/m² for transplant-naive patients; gemcitabine 800 mg/m², vinorelbine 15 mg/m², pegylated liposomal doxorubicin 10 mg/m² for post-transplant patients)
Trial: 15525924
Drug: IA morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA morphine with bupivacaine injected 10 minutes before tourniquet release
Trial: 15525924
Drug: IA morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA morphine with bupivacaine injected after tourniquet release
Trial: 17201879
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg p.o. twice daily for 3 days)
Trial: 12355944
Drug: Gemcitabine or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine or its combination therapies
Trial: 9718247
Drug: Nortriptyline (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (titrated to 50-150 ng/ml)
Trial: 8595636
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil suspension
Trial: 2113874
Drug: Amoxycillin syrup
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin syrup
Trial: 460026
Drug: Etozolin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etozolin (800 mg p.o.)
Trial: 460026
Drug: Furosemide (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (80 mg p.o.)
Trial: 460026
Drug: Etozolin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etozolin (800 mg p.o.) and Furosemide (80 mg p.o.)
Trial: 22917075
Drug: Enriched cheese
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enriched cheese (90 g/d for 3 weeks)
Trial: 22917075
Drug: Control cheese
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cheese (90 g/d for 3 weeks)
Trial: 20802006
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m(2) on days 1 and 29, Irinotecan 60 mg/m(2) on days 1, 8, 15, 29, 36, and 43, and 30 mg/m(2) on days 57, 64, 71, 78, 85 and 92, followed by thoracic radiotherapy starting on day 57 at 2 Gy/day (total 60 Gy)
Trial: 9394979
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied PAF antagonist (RO‐24‐0238)
Trial: 27762662
Drug: Caffeine (1.5‐3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1.5‐3.0 mg · kg‐1 day‐1; titrated)
Trial: 18279051
Drug: Zinc lozenges
RxNorm normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc lozenges (13.3 mg of zinc as zinc acetate)
Trial: 15689918
Drug: Low-dose testosterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose testosterone (T) + letrozole (Lz; 2.5 mg/d)
Trial: 15689918
Drug: Low-dose testosterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose testosterone (T) + placebo (P)
Trial: 10501791
Drug: Clodronate 400
RxNorm normalized name: clodronic acid 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 400 mg daily
Trial: 1985428
Drug: Dietary control
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary control of blood phenylalanine below 900 mumol/L maintained beyond age 10 years
Trial: 1985428
Drug: Dietary control
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary control not maintained (blood phenylalanine persistently above 900 mumol/L)
Trial: 16350383
Drug: Hyaluronan-based heparin-bonded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronan-based heparin-bonded circuits
Trial: 12115160
Drug: Psychological interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological interventions (e.g., relaxation, biofeedback, cognitive‐behavioral therapy)
Trial: 9857535
Drug: Dexamethasone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (250 mg), Promethazine (300 mg), Dextran 70 (500 ml intraperitoneally)
Trial: 8589875
Drug: Left-sided approach
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left-sided approach with submuscular or subcutaneous patch
Trial: 8589875
Drug: Right-sided approach
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right-sided approach with submuscular or subcutaneous patch
Trial: 8589875
Drug: Left-sided approach
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left-sided approach without submuscular or subcutaneous patch
Trial: 8589875
Drug: Right-sided approach
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right-sided approach without submuscular or subcutaneous patch
Trial: 31302000
Drug: Aspiration Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration Therapy (AT) plus Lifestyle Therapy
Trial: 31302000
Drug: Lifestyle Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle Therapy
Trial: 29085538
Drug: Heated gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated gel (102.0° F)
Trial: 29085538
Drug: Room-temperature gel
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room-temperature gel (82.3° F)
Trial: 21762229
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 2 mg inhalation suspension
Trial: 8956674
Drug: Clozapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (mean final dose 176 ± 149 mg/d)
Trial: 8956674
Drug: Haloperidol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (mean final dose 16 ± 8 mg/d)
Trial: 1285568
Drug: L-648,051 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-648,051 (6 mg, four times daily for 7 days)
Trial: 1285568
Drug: L-648,051 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-648,051 (6 mg, inhaled before antigen challenge)
Trial: 22849787
Drug: Automated text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated text messaging (SMS) system providing daily queries about prescription pickup and dosage taken with educational feedback
Trial: 18197974
Drug: Lactobacilli treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacilli treatment (109 freeze-dried lactobacilli for 10 days during 3 menstrual cycles)
Trial: 18197974
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (identical placebo capsules for 10 days during 3 menstrual cycles)
Trial: 18197974
Drug: Lactobacilli treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacilli treatment
Trial: 9216851
Drug: PVB chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVB chemotherapy (cisplatin, vinblastine, bleomycin)
Trial: 9216851
Drug: CAP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP chemotherapy (cyclophosphamide, aclacinomycin, cisplatin)
Trial: 9216851
Drug: PVB chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVB chemotherapy
Trial: 27788313
Drug: Control Therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Therapy for Insomnia (CTRL)
Trial: 24999158
Drug: Community Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Health Workers (CHW's) intervention with monthly visits
Trial: 16642920
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) administered at 20 ng/kg/min from just after the induction of anesthesia to the end of surgery
Trial: 16642920
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PGE1 treatment)
Trial: 14714362
Drug: Integrative Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Chinese and Western Medicine (ICWM)
Trial: 10323118
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.6 mg/kg)
Trial: 4008807
Drug: Chlorpheniramine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine (24 mg per day)
Trial: 4008807
Drug: Chlorpheniramine (doubled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine (doubled dose from days 22 to 24)
Trial: 25129967
Drug: Self-treatment combined
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-treatment combined with modified Epley maneuver
Trial: 25129967
Drug: Hand repositioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand repositioning in self-treatment group
Trial: 25129967
Drug: Chair-assisted repositioning
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chair-assisted repositioning in self-treatment group
Trial: 25129967
Drug: Self-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-treatment group
Trial: 19889241
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (CC) (5 mg caffeine/kg body weight)
Trial: 18620591
Drug: Ringer solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer solution (1500 ml + 200 ml mannitol + 60 ml sodium bicarbonate + 150 U/kg heparin)
Trial: 18620591
Drug: HES 130‐0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 130‐0.4 solution (1500 ml + 200 ml mannitol + 60 ml sodium bicarbonate + 150 U/kg heparin)
Trial: 12462286
Drug: Olopatadine 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.1% ophthalmic solution BID
Trial: 12462286
Drug: Cromolyn 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn 2% ophthalmic solution QID
Trial: 10730526
Drug: Gentamicin 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 4.5 mg/kg/d once daily (OD group)
Trial: 10730526
Drug: Gentamicin 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 4.5 mg/kg/d in three divided doses (TID group)
Trial: 7670450
Drug: High Carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Carbohydrate Diet (HCD) - 4.5 +/‐ 0.5 g CHO.kg‐1.d‐1 for 3 days followed by 8.2 +/‐ 0.4 g CHO.kg‐1.d‐1 for 3 days
Trial: 7670450
Drug: Mixed Diet
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed Diet (MD) - 4.0 +/‐ 0.5 g.kg‐1.d‐1 of carbohydrate for 6 days
Trial: 7389388
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg 8-hourly
Trial: 7389388
Drug: Ampicillin 250
RxNorm normalized name: ampicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 250 mg 6-hourly
Trial: 31841363
Drug: Standard-Dose Radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-Dose Radiation (60 Gy) with concurrent chemotherapy
Trial: 31841363
Drug: High-Dose Radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Radiation (74 Gy) with concurrent chemotherapy
Trial: 27348462
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure (PE) therapy via computer teleconferencing
Trial: 27348462
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure (PE) therapy via iPhone
Trial: 18057480
Drug: Cefpodoxime Proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime Proxetil (CP) 16 mg/kg/day
Trial: 18057480
Drug: Cefixime (CF)
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime (CF) 20 mg/kg/day
Trial: 11006365
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (30 microg weekly intramuscular injections)
Trial: 11006365
Drug: Placebo (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (weekly injections)
Trial: 8875379
Drug: Dried garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried garlic tablets (standardised to 1.3% allicin) at a dosage of 300 mg three times daily
Trial: 2049420
Drug: Vancomycin 25
RxNorm normalized name: vancomycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 25 mgm/L
Trial: 2049420
Drug: Cefazolin 50
RxNorm normalized name: cefazolin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 50 mgm/L
Trial: 6839757
Drug: Oestrogen-progestogen combination
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen-progestogen combination
Trial: 30499227
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavioral Treatment (GCBT)
Trial: 30499227
Drug: Group Present-Centered
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Present-Centered Treatment (GPCT)
Trial: 19143690
Drug: Tramadol 1
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1 mg.kg(‐1)
Trial: 22927775
Drug: Propofol-lidocaine mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-lidocaine mixture (20 mg lidocaine with 180 mg 1% propofol)